Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease
Calhoun A, Ko J, Grossberg GT. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease. Expert Opinion On Emerging Drugs 2017, 22: 101-105. PMID: 28253832, DOI: 10.1080/14728214.2017.1293651.Peer-Reviewed Original ResearchConceptsNMDA receptor antagonistAlzheimer's diseaseClinical trialsReceptor antagonistCurrent phase 3 trialsPhase 3 trialCurrent clinical trialsNeuronal cell deathMajor neuropsychiatric disordersSymptom pathophysiologySymptomatic treatmentAD symptomatologyClinical symptomatologyNeuritic plaquesNeurofibrillary tanglesCurrent treatmentPotential treatmentSupplementary treatmentCholinesterase inhibitorsIdalopirdineAge 65Neuropsychiatric disordersAntagonistLiterature searchDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply